tiprankstipranks
The Fly

Inozyme price target lowered to $14 from $16 at H.C. Wainwright

Inozyme price target lowered to $14 from $16 at H.C. Wainwright

H.C. Wainwright analyst Edward White lowered the firm’s price target on Inozyme to $14 from $16 and keeps a Buy rating on the shares. The analyst moved the estimated launch of ENPP1 to 2027 and the estimated launch of ABCC6 to 2028 following the topline data from the Phase 1/2 trial in adults with ABCC6 deficiency release.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com